Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
- Astellas Gets EMA Blessing for Gastric Cancer Drug Zolbetuximab
July 30, 2024
- Padcev-Keytruda Nears EU Nod for 1st Line Bladder Cancer
July 30, 2024
- Xocova Grabs Near-70% Share among Oral COVID Meds in Japan: Shionogi
July 30, 2024
- Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
- AZ, United Immunity to Tie Up on Drug Delivery Tech Research
July 29, 2024
- Otsuka Ups H1 Earnings Forecast on Brisk Business
July 29, 2024
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
- Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
July 26, 2024
- Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
- Merck, GTRI Tie Up in Development of Parkinson’s Gene Therapy
July 26, 2024
- Intage, Niigata University Tie Up on Megalin Antagonist Development
July 26, 2024
- Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
- Amazon Launches Online Pharmacy Service in Japan
July 25, 2024
- Novo, Mitsubishi Logistics to Launch Pilot Drug Transport Using Electric Truck
July 25, 2024
- Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
- Moderna, University of Tokyo Link Arms on mRNA Technology
July 24, 2024
- Kobayashi Pharma Replaces Management after Beni-Koji Scandal
July 24, 2024
- Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…